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A B S T R A C T
To evaluate the efficacy and safety of intravitreal bevacizumab in treatment of minimally classic and occult choroidal
neovascularization secondary to age-related macular disease 48 eyes of 48 patients (mean age of 74.8) included in this
prospective, noncomparative, interventional case series. Median follow-up was 18 weeks (6–24). Intravitreal bevacizu-
mab injection of 0.05 mL (1.25 mg) was administered at baseline and in 6 week intervals until leakage resolved, and re-
peated in case of leakage recurrence. Visual acuity (VA) improved in the majority of patients (mean baseline VA=1.078
log MAR) by mean increase of 1.32 lines (last follow-up) (p=0.001). Central foveal thickness and total macular volume
decreased by 51 µm (p=0.01) and 0.84 mm3 (p<0.0001) respectively. No serious complications were observed. As initial
therapy, intravitreal bevacizumab appears to be safe and effective. A significant functional and anatomical improvement
was noted in majority of patients and maintained during follow-up.
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Introduction
Photodynamic therapy has shown a positive effect in
reducing the risk of visual loss in patients with occult
choroidal neovascularization as shown by VIP Study
Group,1 and in minimally classic CNV as shown by Azab
et al.2 We also noticed from our own clinical experience
that the verteporfin therapy has not produced as good re-
sults in treatment of minimally classic and occult lesions,
as in treatment of classical CNV, so we were of an opinio
that further investigation of novel approaches in treat-
ment of such lesion subtypes is fully justified. The posi-
tive outcomes of antiVEGF therapy in treatment of neo-
vascular AMD have been fully reported in several studies
conducted by Avery et al3 and Gragoudas at al.4 New
antiVEGF agent, bevacizumab, has also been used in
off-label treatment of neovascular AMD and neovascu-
larization due to pathologic myopia, for several months
now as described by Avery et al,3 Michels et al,5 Nguyen
et al,6 and Rosenfeld et al.7 Bevacizumab, a humanized
monoclonal antibody directed against vascular endothe-
lial growth factor, was already approved by Food and
Drug Administration for the treatment of metastatic
colorectal cancer as shown by He and Marshall.8 By in-
hibiting angiogenesis and decreasing vascular permeabil-
ity, bevacizumab can be an effective in treatment of a va-
riety of ocular conditions including neovascular AMD.
Pegaptanib (Macugen, Eyetech Pharmaceuticals, Inc.,
New York, NY) has shown positive results compared to
usual care of AMD initially, but the mean visual acuity of
the entire group declined over course of the years,4 as
was the case with verteporfin therapy too.9,10. Ranibi-
zumab (Lucentis, Genatech) is an antibody fragment de-
rived from the same murine anti-VEGF antibody as
bevacizumab. A phase III clinical trial recently demon-
strated ranibizumab to be effective in treatment of neo-
vasculaer AMD (Miller JW. Randomized, controlled pha-
se III study of ranibizumab (Lucentis) for minimally
classic or occult neovascular AMD. Paper presented at:
ARSR meeting 2005. Montreal, Canada). Since the rani-
bizumab half-life appears to be shorter then bevaci-
zumab half-life11, and since ranibizumab has not been
approved yet by regulatory agencies, and the proposed
cost of the drug may turn to be higher that of bevaci-
zumab already on the market, we think it is fully justi-
fied to try to further evaluate bevacizumab in treatment
of neovascular AMD as data on this topic is minimal.
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In this study we focused on minimally classic and oc-
cult membranes, as those in our clinical practice present
a main challenge, and according to our own clinical find-
ings, do not respond very well to photodynamic therapy
alone or when combined with intravitreal triamcinolone,
although such a combination treatment has appeared to
be more potent12–14. So in this study we aimed at provid-
ing preliminary efficacy and safety results to help deter-
mine whether intravitreal bevacizumab can improve vi-
sual acuity and macular morphology parameters such as
thickness and volume in patients with mentioned sub-
types of neovascular AMD and therefore reverse the nat-
ural history of the disease, which is particularly unfavor-
able in those lesion subtypes.
Methods
There were 48 eyes of 48 patients included in this pro-
spective, interventional, noncomparative case series. Pa-
tients were recruited by our retinal subdivision and were
chosen in order to meet inclusion criteria. At baseline, all
patients underwent VA measurement using EDTRS
chart, slit lamp and fundus examination and IOP mea-
surements. Fluorescein angiography was performed to
identify lesion subtype and location and to verify active
choroidal neovascular leakage. Also OCT scan was per-
formed to verify exudation, and to measure fovel thick-
ness and macular volume. Inclusion criteria were as fol-
lows: patient age  50, VA better or equal to 20/400, active
leakage at FA and OCT scan, subfoveal lesion location,
GLD of  7500 µm, no previous treatment. All patients
were evaluated and treated every 6 weeks in case of pres-
ence of retinal edema, subretinal fluid(SRF) and/or pig-
ment epithelial detachment(PED).
In conducting this study we adhered to the and the
study was approved by the Ethics Committee of the Eye
Clinic and written informed consent was obtained from
the patients in the study describing the experimental na-
ture of the bevacizumab off-label use and potential risks.
All the injections were performed in the operating
room under microscope after povidone-iodine eye prepa-
ration. Patients received topical and subconjunctival an-
esthesia. Then 1.25 mg of bevacizumab (Avastin 100 mg /
4mL vial, Genantech Inc, San Francisco, USA) in a vol-
ume of 0.05 mL solution was administered intravitreally
through pars plana by 27-gauge needle. No paracenthesis
was required due to small volume injected. After the in-
jection, intraocular pressure, retinal artery perfusion
and light appreciation from all 4 directions were checked.
Patients were asked to come back for follow-up visits in
6-week intervals, when similar ophthalmologic examina-
tion was performed including VA measurement, IOP
measurement, angiography and OCT scan.
An additional intravitreal application of bevacizumab
was performed using the protocol already described in
case of retinal edema, SRF and/or PED presence or re-
currence.
The main outcome measures were a mean change in
VA between baseline and last follow-up, measured using
EDTRS chart in logMAR units, a mean change in central
foveal thickness (CFT) and total macular volume (TMV)
(within 3000 µm radius from center of fovea) at baseline
and last follow-up, measured by OCT (Stratus III OCT,
Carl Zeiss) using 6 diagonal fast scan. Patients with PED
were excluded from thickness and volume calculations
due to the limitations of current software not including
PED thickness in the calculation. The mean VA, foveal
thickness and macular volume at the final follow-up were
then compared with the baseline values, and statistically
analyzed using paired t test to determine statistical sig-
nificance between two corresponding groups.
Results
A total of 48 eyes of 48 patients with choroidal neovas-
cularization due to AMD were included in the study,
meeting the inclusion criteria described previously. The-
re were 29 females and 19 males, with a mean age of 74.8
years (range 62–82). The mean lesion size was 3993 µm
(range 500–7500). There were 38 minimally classic CNV
membranes and 10 occult CNV membranes (2 associated
with PED) as documented angiographicaly and by OCT
scan. Both lesion subtypes responded with a reduction in
leakage, as evaluated by an experienced retinologist. All
48 patients completed 6 week follow-up. Median fol-
low-up was 18 weeks (6–24), while mean follow- up was
15.4 weeks.
At 6 weeks after injection 11 of 48 eyes showed resolu-
tion of leakage (macular edema, SRF, PED). Of the 40
eyes with 12 week follow-up, 30 showed leakage resolu-
tion. Of the 28 eyes completing 18 week follow-up, 17
demonstrated leakage resolution, and of 8 eyes complet-
ing 24 week follow-up, 7 demonstrated leakage resolu-
tion.
The mean VA at baseline was 20/250+ (1.078 log
MAR), the mean central foveal thickness (CFT) was 389
µm, while the mean total macular volume(TMV) was
9.33 mm3. There was a significant mean increase in VA
from baseline to the time of last follow-up visit of 1.32
lines (p=0.001) to 20/160– (0.946 logMAR) (Figure 1).
Furthermore there was a significant mean decrease in
CFT from baseline to the time of last follow-up visit of 51
µm (p=0.01). (Figure 2). The mean macular volume at
last follow-up decreased significantly by 0.84 mm3 (p<
0.0001) compared to baseline. (Figure 3).
Fifteen patients, in whom leakage resolution was
achieved initially at one point during follow-up, recurred
with subretinal fluid and/or edema and required re-
peated injection. Those patients were followed-up for at
least 12 weeks. Five of those patients with leakage recur-
rence responded to the additional injection with leakage
resolution.
When treatment results were analyzed with respect
to lesion size, lesions larger that 6000 µm maintained
stable vision, but improvement in VA was not statisti-
cally significant. On the other hand, those lesions show-
ed significant macular volume decrease what was main-
tained to the last follow-up visit.
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There were no adverse reactions to the treatment reg-
imen. No patient developed inflammation, infection,
trombo-embolic events or ocular toxicity. No patient re-
quired topical anti-glaucomatous therapy, other than
what they had used previously for their preexisting glau-
coma. No patient complained of significant vision blur-
ring after bevacizumab injections or it disappeared usu-
ally within a few days. No major cataract progression
was noted and 4 patients underwent cataract extraction
during the study period.
Discussion
We are not aware of any study which evaluates in-
travitreal bevacizumab in treatment of minimally classic
and occult choroidal neovascularization due to AMD. In
fact, there are only a few studies evaluating efficiency of
intravitreal bevacizumab in treatment of exudative AMD
what was reported by Avery et al,3 Michels et al,5 and
Rosenfeld et al.7 The mention studies report short term
efficacy and safety profile of the treatment and do not
differentiate between lesion subtypes. Also the largest
and most complete study so far by Avery at al adminis-
tered intravitreal bevacizumab to patients, majority of
whom were already treated ether by PDT, pegatpanib or
both. Also the patients of all lesion subtypes were in-
cluded in the Avery’s study and follow-up was 8 weeks
for the majority of patients. Due to the previous treat-
ment of AMD with either PDT and/or pegaptanib in the
Avery’s study, the general idea of how many injections
were needed is somewhat tempered, but the Avery’s
study was an excellent study and the first one to give
most complete data up to date on the bevacizumab effi-
cacy, safety and dosing schedule. In our study patients re-
ceived no previous treatment, they were of a minimally
classic and occult lesion subtype and were followed for a
longer period (median 18 weeks), and so the general idea
of dosing schedule is proposed.
In our clinical practice we perform a treatment of
choice for classical CNV which is obviously PDT, but we
propose an alternative approach to our patients present-
ing with minimally classic or occult CNV (with/without
PED) due to AMD as we noticed that clinical outcome of
PDT in treatment of those lesions leads to stabilization
rather then improvement of visual outcome what is con-
sistent with TAP,9,15 VIP, 1Wormald et al16 and Azab et al2
studies. We hypothesis that one of possible theories for
such an outcome in those lesion subtypes could be ex-
plained by a more difficult light activation of the drug ab-
sorbed by target tissue beneath retinal pigment epithe-
lium. Minimally classic and occult membranes are lo-
cated more deeply than classical membranes and their
exposure to the light is somewhat blocked by blood,
exudates and partially intact retinal pigment epithelium
above them. In such lesions antiVEGF substance could
have a better access to target structure by diffusion. At
first, it was initially considered that a full-length anti-
bodies, such as bevacizumab, wouldn’t be able to pene-
trate full thickness retina11,17 and therefore no wide-
spread investigation of the drug was carried out. But it
has been recently shown that although having a full
length antibody structure, bevacizumab can penetrate
full thickness retina as described by Shahar et al.18 either
because of higher doses used18 as opposed to first stud-
ies,11 lack of ILM at fovea19 or compromised retinal barri-
ers in macular degeneration3,20.
Although not manufactured and labeled for intravi-
treal use, the drug was well tolerated with our patients.
We have not observed trombo-embolic events nor intra-
ocular toxicity what is consistent with findings by Man-
zano et al,21 and Shahar et al.18













Fig. 1. There was a significant mean increase in best corrected
visual acuity from baseline to the time of last follow-up visit of













Fig. 2. There was a significant mean decrease in central foveal
thickness from baseline (389 µm) to the time of last follow-up











Fig. 3. The mean macular volume at last follow-up decreased
significantly for 0.84 mm3 (p<0.0001) compared to baseline
(9.33 mm3).
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The proposed volume of the intravitreal bevacizumab
is very small (0.05 mL), so we have not experienced any
problems with intraocular pressure increase. There is al-
ways a risk of endophthalmitis, but since no paracen-
thesis was needed to control the eye pressure, the risk
was even smaller. Also, the post-application period was
well tolerated by patients, since bevacizumab is a clear
solution not causing vitreal staining. Since the half-life of
bevacizumab is quite long as reported by Ignoffo,22 we
thought it would be appropriate to give bevacizumab in
6-week intervals as the optimum dosing regimen is still
undetermined. This longer half-life may theoretically in-
crease the risk of systemic toxicity but the intravitreal
doses are 400 times smaller then when compared to sys-
temic bevacizumab administration8,22. In systemic be-
vacizumab administration a small but significant risk of
trombo-embolic events exists23 but with 400-fold dose de-
crease in intraocular administration this may be of lesser
concern. Also a mentioned study showed location of
VEGF receptors at neurons at astrcytes23 suggesting
VEGF’s neuroprotective role, therefore blockage of such
receptors could in theory lead to decreased protection of
ganglion cells and fotoreceptors in antiVEGF treated in-
dividuals. But the natural history of AMD is so damaging
when left untreated so it is a question whether the possi-
ble long-term neuroprotection decrease could outweigh
the clear short term treatment benefit.
Lesions smaller than 6000 µm, responded with func-
tional improvement to the treatment what reiterates the
importance of early detection and early treatment initia-
tion.
We find our study to be a pivotal study in evaluation
of treatment results of intravitreal bevacizumab for min-
imally classic and occult CND due to AMD, and further
studies including more participants and longer follow-up
are needed to confirm our findings. Limitations of this
study are clearly its interventional character, noncom-
parative nature and variability in follow-up. But the in-
formation provided clearly shows the reversed disease
course in treated individual as the improvement of visual
acuity and decrease in macular thickens and volume are
not consistent with natural development of the disease.
Regardless of whether bevacizumab survives the ar-
rival of newer, hopefully more potent antiVEGF inhibi-
tors e.g. ranicizumab (already in phase III of clinical tri-
als), for now we have a very limited pool of agents we can
choose from in pharmacological treatment of exudative
AMD. And the longer bevacizumab half-life and its lower
cost, if proven equally potent and safe as ranicizumab
and pegaptanid, would certainly be of a great advantage.
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Fig. 4. Minimally classic lesion shown on OCT scan before ther-
apy (left), and 6 weeks after treatment (right). Visual acuity in-
creased from 20/200 to 20/125.
Fig. 5. Before therapy a large pigment epithelial detachment as
shown on OCT scan (left), and 6 weeks after treatment (right)
with complete resolution of sub-RPE fluid. Visual acuity increa-
sed from 20/200 to 20/80.
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INTRAVITREALNI BEVACIZUMAB (AVASTIN) U LIJE^ENJU NEOVASKULARNE
SENILNE MAKULARNE DEGENERACIJE
S A @ E T A K
Istra`iti u~inkovitost i sigurnost intravitrealnog bevacizumaba u lije~enju minimalno klasi~ne i okultne koroidalne
neovaskularizacije u sklopu senilne makularne degeneracije 48 o~iju 48-rice pacijenata (prosje~ne starosti 74.8) u pros-
pektivnoj, nekomparativnoj, intervencijskoj seriji. Pra}enje se odvijalo tijekom mediana od 18 tjedana (6–24). Intravi-
tealnom injekcijom je primjenjeno 0.05 mL (1.25 mg) bevacizumaba u po~etku studije i u 6-to tjedanim razmacima do
prestanka eksudacije, te ponovljeno u slu~aju ponavljanja eksudacije. Vidna o{trina (VA) je pobolj{ana u ve}ine pacije-
nata (srednja po~etna VA=1.078 log MAR) za prosje~no 1.32 linije (zadnja kontrola) (P=0.001). Sredni{nja fovealna
debljina i ukupni makularni volumen smanjeni se za 51 µm (p=0.01) i 0.84 mm3 (p<0.0001). Zna~ajne komplikacije
nisu zabilje`ene.Intravitrealni primjenjen bevacizumab je u~inkovit i siguran kao inicijalna terapija. Signifikantno
funkcionalno i anatomsko pobolj{anje je zabilje`eno u ve}ine pacijenata i odr`avano tijekom pra}enja.
R. Lazi} et al.: Avastin in Minimally Classic and Occult CNV due to AMD, Coll. Antropol. 31 (2007) Suppl. 1: 77–81
81
U:\coll-antropolo\coll-antro-suppl-1-2007\lazic 2.vp
12. veljaŁa 2007 13:59:47
Color profile: Disabled
Composite  150 lpi at 45 degrees
